A new medicine called Exdensur (depemokimab) has been approved in Europe for two conditions: severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. This is the first time a treatment like this, which lasts a long time, has been approved for breathing problems in Europe. The medicine is approved for: adults and teenagers aged 12 and over with severe asthma who are not well-controlled with other medicines, and adults with severe chronic rhinosinusitis with nasal polyps who are not well-managed with other treatments or surgery. The approval is based on studies that showed the medicine works well with just two doses a year. Kaivan Khavandi, a leader in the research and development of respiratory medicines at GSK, said: “The approval of Exdensur in the EU means there is now an innovative ultra-long-acting option that offers sustained efficacy over 6 months to protect patients from severe asthma exacerbations and the debilitating symptoms associated with CRSwNP. Exdensur may help redefine care for the millions of patients living with these persistent and burdensome conditions, supporting them in achieving their treatment goals with just two doses a year.” Asthma affects more than 42 million people in Europe, with 5–10% experiencing severe disease. Patients with chronic rhinosinusitis with nasal polyps also face daily symptoms, and almost half remain uncontrolled. Exdensur works by targeting and suppressing the inflammation that causes these conditions. Stephanie Korn, MD, PhD, said: “People living with the burden of severe asthma face persistent exacerbations driven by uncontrolled type 2 inflammation. A new option with twice-yearly dosing that could provide sustained suppression of type 2 inflammation is a promising innovation for patients in Europe with severe asthma who are in urgent need of novel solutions.” Eugenio De Corso, MD, PhD, added: “CRSwNP profoundly impacts a patient’s daily life, causing debilitating nasal obstruction which can make breathing, smell, sleeping and other fundamental activities a major challenge. An innovative treatment option like Exdensur, that could help patients achieve their treatment goals in fewer doses, represents an important advance.”